These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22312942)

  • 21. Venom immunotherapy: clinical efficacy, safety and contraindications.
    Kosnik M; Korosec P
    Expert Rev Clin Immunol; 2015; 11(8):877-84. PubMed ID: 26018865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy.
    Soriano Gomis V; Gonzalez Delgado P; Niveiro Hernandez E
    J Investig Allergol Clin Immunol; 2008; 18(3):225-6. PubMed ID: 18564638
    [No Abstract]   [Full Text] [Related]  

  • 23. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice.
    Bonifazi F; Jutel M; Biló BM; Birnbaum J; Muller U;
    Allergy; 2005 Dec; 60(12):1459-70. PubMed ID: 16266376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome.
    da Silva EN; Randall KL
    J Allergy Clin Immunol Pract; 2013; 1(6):687-8. PubMed ID: 24565720
    [No Abstract]   [Full Text] [Related]  

  • 25. Issues in stinging insect allergy immunotherapy: a review.
    Finegold I
    Curr Opin Allergy Clin Immunol; 2008 Aug; 8(4):343-7. PubMed ID: 18596592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy.
    Pereira Santos MC; Pedro E; Spínola Santos A; Branco Ferreira M; Palma Carlos ML; Palma Carlos AG
    Eur Ann Allergy Clin Immunol; 2005 Sep; 37(7):273-8. PubMed ID: 16285233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insect anaphylaxis: addressing clinical challenges.
    Tracy JM; Lewis EJ; Demain JG
    Curr Opin Allergy Clin Immunol; 2011 Aug; 11(4):332-6. PubMed ID: 21659864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
    Ruëff F; Wenderoth A; Przybilla B
    J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ultrarush venom desensitization after systemic reactions during conventional venom immunotherapy.
    Oren E; Chegini S; Hamilos DL
    Ann Allergy Asthma Immunol; 2006 Nov; 97(5):606-10. PubMed ID: 17165267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. American Academy of Asthma, Allergy & Immunology membership experience with venom immunotherapy in chronic medical conditions and pregnancy, and in young children.
    Calabria CW; Hauswirth DW; Rank M; Sher L; Larenas-Linnemann D
    Allergy Asthma Proc; 2017 Mar; 38(2):121-129. PubMed ID: 28234049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omalizumab in chronic urticaria.
    Metz M; Maurer M
    Curr Opin Allergy Clin Immunol; 2012 Aug; 12(4):406-11. PubMed ID: 22766620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial.
    Brockow K; Kiehn M; Riethmüller C; Vieluf D; Berger J; Ring J
    J Allergy Clin Immunol; 1997 Oct; 100(4):458-63. PubMed ID: 9338537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Venom immunotherapy in indolent systemic mastocytosis with high serum tryptase level.
    Selcuk A; Baysan A
    Hum Vaccin Immunother; 2021 Jun; 17(6):1599-1603. PubMed ID: 33651660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis of Hymenoptera venom allergy.
    Biló BM; Rueff F; Mosbech H; Bonifazi F; Oude-Elberink JN;
    Allergy; 2005 Nov; 60(11):1339-49. PubMed ID: 16197464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab.
    Bell MC; Jackson DJ
    Ann Allergy Asthma Immunol; 2012 May; 108(5):383-4. PubMed ID: 22541416
    [No Abstract]   [Full Text] [Related]  

  • 36. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis.
    Carter MC; Robyn JA; Bressler PB; Walker JC; Shapiro GG; Metcalfe DD
    J Allergy Clin Immunol; 2007 Jun; 119(6):1550-1. PubMed ID: 17481708
    [No Abstract]   [Full Text] [Related]  

  • 37. Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis.
    Kibsgaard L; Skjold T; Deleuran M; Vestergaard C
    Acta Derm Venereol; 2014 May; 94(3):363-4. PubMed ID: 24162824
    [No Abstract]   [Full Text] [Related]  

  • 38. An Increase in Tryptase on the First Day of Hymenoptera Venom Immunotherapy Might Be a Predictor of Future Systemic Reactions During Treatment.
    Vega-Castro A; Alonso-Llamazares A; Cárdenas R; Beitia JM; Mateo B; Alvarez-Twose I; Blanco C
    J Investig Allergol Clin Immunol; 2018 Oct; 28(5):305-311. PubMed ID: 29589586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hymenoptera venom allergy.
    Przybilla B; Ruëff F
    J Dtsch Dermatol Ges; 2010 Feb; 8(2):114-27; quiz 128-30. PubMed ID: 19751222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety profile of hymenoptera venom immunotherapy (VIT) in monosensitized patients: lack of new sensitization to nontreated insect venom.
    Spoerl D; Bircher AJ; Scherer K
    J Investig Allergol Clin Immunol; 2011; 21(1):22-7. PubMed ID: 21370719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.